This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Oct;10(10):542.

doi: 10.1038/nrneph.2014.143. Epub 2014 Aug 12.

Transplantation: Alemtuzumab induction reduces acute rejection risk

PMID: 25112441
DOI: 10.1038/nrneph.2014.143

Comment

Transplantation: Alemtuzumab induction reduces acute rejection risk

Peter Sidaway. Nat Rev Nephrol. 2014 Oct.

. 2014 Oct;10(10):542.

doi: 10.1038/nrneph.2014.143. Epub 2014 Aug 12.

Author

PMID: 25112441
DOI: 10.1038/nrneph.2014.143

No abstract available

PubMed Disclaimer

Comment on

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
3C Study Collaborative Group; Haynes R, Harden P, Judge P, Blackwell L, Emberson J, Landray MJ, Baigent C, Friend PJ. 3C Study Collaborative Group, et al. Lancet. 2014 Nov 8;384(9955):1684-90. doi: 10.1016/S0140-6736(14)61095-3. Epub 2014 Jul 28. Lancet. 2014. PMID: 25078310 Clinical Trial.

References

1. Lancet. 2014 Nov 8;384(9955):1684-90 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information